Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial (FLUTEEN)
An Adolescent Sub-study Within FLUTE-2: A Randomized, Double-blind, Placebo-Controlled Study of APT-1011 (Fluticasone Propionate Oral Dispersible Tablet Formulation), With an Open-label Extension, in Adolescent Subjects With Eosinophilic Esophagitis
Sponsor: Ellodi Pharmaceuticals, LP
A PHASE3 clinical study on Eosinophilic Esophagitis, this trial is completed. The trial is conducted by Ellodi Pharmaceuticals, LP and has accumulated 10 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Oct 2023 — Jul 2024 [monthly]
Completed PHASE3
-
May 2023 — Oct 2023 [monthly]
Completed PHASE3
-
Dec 2022 — May 2023 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 5 earlier versions
-
Nov 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE3
-
Jul 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE3
-
May 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE3
-
Nov 2021 — Apr 2022 [monthly]
Recruiting PHASE3
First recorded
Sep 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ellodi Pharmaceuticals, LP
For direct contact, visit the study record on ClinicalTrials.gov .